@article{10902/32670,
year = {2024},
url = {https://hdl.handle.net/10902/32670},
abstract = {Objective: The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti-Ro60/SSA antibodies, whereas the significance of anti-Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti-Ro52/TRIM21 antibody status. Methods: Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52‾/Ro60‾), isolated anti-Ro52/TRIM21 positive (Ro52+), isolated anti-Ro60/SSA positive (Ro60+), and double-positive (Ro52+/Ro60+) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients. Results: In the DIApSS cohort, Ro52+/Ro60+ patients showed significantly more parotidomegaly (33.3% vs 0%?11%) along with higher β2-microglobulin (P =0.0002), total immunoglobulin (P <0.0001), and erythrocyte sedimentation rate levels (P =0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%?25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis (P =0.046), inflammation (P =0.005), hypergammaglobulinemia (P <0.0001), positive RF (P <0.0001), leukopenia (P =0.004), and lymphopenia (P =0.009) in Ro52+/Ro60+ patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities (P =0.002). Transcriptome analysis linked anti-Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations. Conclusion: These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies.},
organization = {Funding: Supported by the Innovative Medicines Initiative Joint Undertaking (grant 115565 [PRECISESADS project]), resources of which include financial contribution from the European Union’s Seventh Framework Program (grant FP7/2007–2013) and EFPIA companies’ in-kind contribution. LBAI laboratory (Lymphocytes B, Auto-immunité et Immunothérapies) was supported by the Agence Nationale de la Recherche under the “Investissement d’Avenir” program (reference ANR-11-LABX-0016-001 [Labex IGO]).},
publisher = {John Wiley and Sons Ltd},
publisher = {Arthritis and Rheumatology, 2024, 0(0), 1-12},
title = {Association of combined anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies with increased Sjögren disease severity through interferon pathway activation},
author = {Bettacchioli, Eléonore and Saraux, Alain and Tison, Alice and Cornec, Divi and Dueymes, Maryvonne and Foulquier, Nathan and Hillion, Sophie and Roguedas-Contios, Anne-Marie and Benyoussef, Anas-Alexis and Alarcon-Riquelme, Marta E. and Pers, Jacques-Olivier and Devauchelle-Pensec, Valérie and González-Gay Mantecón, Miguel Ángel and Blanco Alonso, Ricardo and Corrales Martínez, Alfonso},
}